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Introduction: Specific subpopulations of non-small cell lung cancer
(NSCLC) patients defined by clinical features and molecular profiles
seem to derive greater benefit from epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors, but no general consensus on
molecular testing to optimize treatment has emerged. The objective
of this study was to evaluate chromosome 7 polysomy and other
potential indicators of gefitinib efficacy in advanced NSCLC pa-
tients.
Methods: Paraffin-embedded tumors from 82 patients treated with
gefitinib were analyzed by immunohistochemistry for expression of
EGFR and other markers, and by fluorescence in situ hybridization
for EGFR gene or chromosome copy number. Mutational status was
assessed by single-strand conformational polymorphism, sequence-
specific polymerase chain reaction, and direct sequencing. Molecu-
lar and clinical characteristics were evaluated in relation to objective
response (OR), progression-free survival (PFS), and overall survival
(OS).
Results: EGFR mutational status ( p  0.002), never smoking
(p  0.052), and chromosome 7 polysomy (p  0.029) were
significant indicators of OR. EGFR mutation, pAKT or PTEN
expression, and chromosome 7 polysomy were associated with
longer OS. There was a significant difference in OS between the
chromosome 7 polysomy groups (p  0.015) and the groups with
both chromosome 7 polysomy and pAkt (p  0.002) and both
chromosome7 polysomy and PTEN (p  0.04). In a stepwise
proportional hazards analysis, chromosome 7 polysomy and PTEN
expression were both significantly associated with longer OS (p 
0.004 and 0.017 respectively).
Conclusion: These results suggest that further study of chromosome
7 polysomy and of pAKT and PTEN expression in patients treated
with EGFR tyrosine kinase inhibitors is warranted in developing a
clinical test for selecting patients for gefitinib therapy.
Key Words: Non-small cell, Targeted therapy, Molecular biomar-
kers, Aneusomy, EGFR mutations.
(J Thorac Oncol. 2007;2: 414–422)
In phase II trials, gefitinib (Iressa, AstraZeneca), a smallmolecular tyrosine kinase inhibitor (TKI),1 demonstrated
objective remissions, but in phase III trials, only a nonsignif-
icant trend in survival was observed compared with placebo.
Women, Asians, never-smokers, and patients with bronchoal-
veolar tumors had more favorable results.2–4 Subsequent
work has shown that these associations arise from molec-
ular differences related to epidermal growth factor receptor
(EGFR) in the tumors in these subpopulations. Specifically,
EGFR-activating mutations, high EGFR gene copy number,
and alterations in proteins involved in EGFR signaling may
identify patients with the best outcomes from TKI treatment.5
Nonrandom structural and numerical abnormalities in
chromosome 7, where EGFR is located, may also be impor-
tant in this context, because they have been observed in
several types of malignancy including malignant mesotheli-
oma and lung cancer. Polysomy 7 was found exclusively in
malignant mesothelioma compared with benign mesothelial
cells.6 In one study on non-small cell lung cancer (NSCLC),
polysomy 7 has been reported to have no significant influence
on prognosis,7 whereas another study has reported significant
association of increased EGFR gene and chromosome 7 copy
number with poor differentiation.8
The relationship of molecular and cytogenetic abnor-
malities to response to TKI is complex and controversial.
Correlating EGFR status with response to therapy and sur-
vival is complicated by the potentially important role of
tumor-related changes in downstream factors in the EGFR
signaling pathways, such as phosphatase and tensin homolog
(PTEN) and phosphorylated v-AKT murine thymoma viral
oncogene homolog 1 (pAKT).9–11 Methods used to assess
these features can be subjective, technically challenging, and
difficult to interpret. Alternatively, detection of polysomy by
fluorescence in situ hybridization (FISH) is a straightforward
analysis that is performed in many molecular and cytogenetic
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laboratories. To better define the relationship between chro-
mosome 7 polysomy and other molecular biomarkers, such as
EGFR amplification, EGFR mutations, EGFR expression,
and expression of related proteins, with efficacy of TKI, this
study evaluated chromosome 7 polysomy with a panel of
putative potential predictors of gefitinib efficacy in NSCLC.
Using several different FISH parameters to describe poly-
somy and gene status, we evaluated chromosome 7 polysomy
and EGFR gene status to determine which method of
genomic copy number assessment was most effective. The
data suggest that chromosome 7 polysomy, which can be
measured easily and unambiguously, may be important in
selecting NSCLC patients for TKI therapy.
MATERIALS AND METHODS
Patients and Clinical Assessment
Specimens from 82 expanded access trial NSCLC pa-
tients treated for more than 1 week with gefitinib were
obtained from the pathology department of Rush University
Medical Center and the University of Chicago (Chicago, IL).
Chart review and study analyses were approved by the Rush
University Medical Center and the University of Chicago
institutional review boards. The diagnosis of NSCLC in the
archival material was obtained from pathology reports and
confirmed by histologic evaluation before further analysis.
Eligibility criteria for the gefitinib expanded access trial
included histologic or cytologic confirmation of stage IIIb or
IV NSCLC; at least one previous course of chemotherapy, or
determination by an investigator that a patient was not suit-
able for chemotherapy or radiotherapy; and written informed
consent. Exclusion criteria included another active malig-
nancy, concurrent radiotherapy or systemic anticancer ther-
apy, incomplete healing from previous surgery, other signif-
icant clinical disorders or laboratory findings, pregnancy, and
breast feeding.
Clinical data were established from chart review. Non-
smoking status was defined by lifetime consumption of fewer
than 100 cigarettes. Objective response (OR) was assessed
according to Response Evaluation Criteria in Solid Tumors.
Progression was determined by radiologic studies. Patients
who progressed within 70 days were classified as having
progressive disease for their best response. Patients who
didn’t meet Response Evaluation Criteria in Solid Tumors for
partial or complete remission and who had not progressed
sooner than 70 days from starting gefitinib were classified as
stable disease for their best response. Progression-free sur-
vival (PFS) and overall survival (OS) were measured in
months from the start of gefitinib treatment to the time of
disease progression or death.
Immunohistochemistry
Immunohistochemistry (IHC) and FISH specimens
were 5.0-m sections of formalin-fixed paraffin-embedded
tumor tissue or sections from cytology cell blocks. FISH and
EGFR expression data were obtained from 81 of the 82
patients, respectively. PTEN and pAKT expression data were
obtained from 74 patients, and mutation and CA repeat data
were obtained from 58 patients. One patient with mutation
data was not assessable by FISH.
Immunostaining methods and reagents were described
previously.12 Staining frequency and intensity of all tumor
cells on each slide were estimated on a scale of 0 to 4, without
knowledge of clinical patient data. A positive tumor cell
count of less than 1% was scored as 0, 1% to 10% as 1, 11%
to 35% as 2, 36% to 70% as 3, and over 70% as 4. Only cell
membrane–associated staining was considered for EGFR.
Before analysis, IHC expression was dichotomized into two
levels: detected (1 to 4) and undetected (0).
In Situ Hybridization
EGFR and centromere 7 (CEN7) probes were used to
examine EGFR/cell, CEN7/cell, and EGFR/CEN7. Specimen
slides were hybridized with two-color FISH probe solutions
(Vysis SpectrumOrange LSI and EGFR/SpectrumGreen CEP
7; Abbott Molecular Inc., Des Plaines, IL). Paraffin pretreat-
ments II and III were performed essentially according to the
kit package inserts. FISH slides were evaluated under a Zeiss
Axioscope microscope (Carl Zeiss, Thornwood, NY) with a
DAPI single–band-pass filter to visualize nuclei, an orange
single–band-pass filter set to visualize EGFR probe, and a
green single–band-pass filter set to visualize CEP 7 (all filter
sets from Abbott Molecular, Inc.). Only nuclei with morphol-
ogy characteristic of malignant cells were counted (Figure 1).
Typically, 30 to 90 (median  80) cells were enumer-
ated in each specimen. The mean number of EGFR or CEN7
signals per cell (EGFR/cell or CEN7/cell, respectively) was
calculated by dividing the total number of signals by the
number of cells counted. Mean EGFR probe signals per cell
were divided by the mean CEP 7 signals per cell to yield
EGFR/CEN7 ratios. EGFR percent gain or CEN7 percent
gain was calculated as the percentage of cells with more than
two EGFR or CEP 7 signals, respectively. EGFR/CEN7
percent gain was the percentage of cells that showed more
EGFR signals than CEP 7 signals. Optimal cutpoints for
defining high ratios or high percent gains were selected by
first generating contingency tables for OR and survival (1
year versus 1 year) for a wide range of cutpoints. Cutpoints
yielding the lowest chi-square probabilities were selected for
further analysis. EGFR high polysomy (at least four copies of
EGFR in 40% of the cells), and amplification (EGFR
gene:CEN7 ratio 2, or 15 copies of EGFR gene per cell
in 10% of the cells), according to criteria published by
Cappuzzo et al.9 (referred to here as UC FISH status) were
also evaluated. Nevertheless, the presence of EGFR signal
clusters was not included in the analysis, because evaluation
of specimens occurred before publication of the study by
Cappuzzo et al.9 It is likely that most signal clusters would
have been enumerated to provide a result of high polysomy or
amplification.
Molecular Genetics
DNA was extracted from paraffin-embedded specimens
by manual microdissection and proteinase K digestion. EGFR
gene mutation status was assessed using single-strand con-
formation polymorphism, sequence-specific polymerase
chain reaction (PCR), and direct sequencing. Polymorphic
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numbers of repeats of the cytosine-adenine (CA) dinucleotide
sequence in intron 1 of the EGFR gene were analyzed by
PCR amplification of the CA repeat region followed by
capillary electrophoresis of the PCR products. The size of the
peaks in base pairs was converted to CA repeat number based
on GenBank accession sequence M38425.1. The median peak
was used to define each allele. The sum of alleles is the total
of median CA repeats from both chromosomes. Alleles of 16
CA repeats and the sum of alleles of 34 CA repeats were
midpoints in the range of alleles in this patient group. Se-
quences of primers used to amplify and sequence exons 18,
19, and 21 and intron 1 CA repeat polymorphisms of the
EGFR gene are available on request.
Statistical Analysis
The associations between response to gefitinib (yes/no)
and categorical covariates were tabulated, and Fisher’s exact
test was used to measure their significance. The Kaplan–
Meier method was used to estimate the probability of survival
as a function of time. Survival differences among comparator
groups were analyzed by the log-rank test. Logistic regres-
sion and Cox proportional hazards models were used to select
and model the effects of molecular markers and other vari-
ables on OR and PFS, respectively. All analyses were per-
formed using SAS version 9.1.3 (SAS Institute, Cary, NC),
and all reported p values are two sided.
RESULTS
Patient Characteristics and Response to
Gefitinib
Table 1 shows patient characteristics and clinical re-
sponse to gefitinib treatment. Median age was 67 years, and
the OR rate was 15%; two patients had complete response, 10
had partial response, 36 (44%) had stable disease, and the
progression rate was 41%. Nonsmoking status was signifi-
cantly associated with OR (p  0.001).
Median PFS for all patients was 3.3 months, with a
95% confidence interval (CI) of 2.3 to 4.2. PFS was signifi-
cantly longer for nonsmokers than for smokers (median 11.7
and 2.9, respectively, p  0.013). Other patient characteris-
tics were not significantly associated with OR or PFS.
Median OS was 7.1 months (CI 5.6 –9.4). OS was
significantly longer for nonsmokers than for smokers (me-
dian 21.1 and 6.3 months, respectively, p  0.028). Pa-
tients with performance status (PS) 0 to 1 survived signif-
icantly longer than patients with PS 2 to 3 (median 9.0 and
5.5, p  0.035).
TABLE 1. Patient Characteristics and Clinical Response to
Gefitinib Treatment
Characteristic
Number of
Patients (%)
Objective
Response (%)
Total 82 (100) 12 (15)
Age (yr)
60 62 (77) 8 (13)
60 20 (23) 4 (20)
Gender
Male 37 (46) 5 (14)
Female 44 (54) 7 (16)
Smoking status*
Yes 70 (85) 5 (7)
Never smoked 12 (15) 7 (58)
Histopathological subtype
Adenocarcinoma/bronchoalveolar 56 (69) 10 (18)
Other 26 (32) 2 (8)
Performance status
0–1 46 (57) 6 (13)
2–4 34 (43) 6 (17)
Previous chemotherapy
None 14 (17) 2 (14)
One 39 (49) 7 (18)
Two or more 28 (34) 3 (11)
*p  0.001.
FIGURE 1. FISH images of paraffin-embedded lung tumor sections stained with SpectrumOrange LSI EGFR probe and
SpectrumGreen CEP 7 centromere probe showing (A) high EGFR gene copy number (6/cell; orange signals), and (B) chro-
mosome 7 polysomy (3.6/cell; green signals). FISH slides were evaluated under a Zeiss Axioscope epifluorescence micro-
scope (Carl Zeiss, Thornwood, NY) with a DAPI single–band-pass filter set to visualize nuclei, an orange single–band-pass filter
set to visualize EGFR probe, and a green single–band-pass filter set to visualize CEP 7 (Abbott Molecular filter sets). Magnification
is 40.
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Molecular Markers and Clinical Response to
Gefitinib
The following genotypic and phenotypic markers were
analyzed for patients with assessable tumor specimens: chro-
mosome 7 polysomy (CEN7/cell 3.6 and CEN7/cell 4)
EGFR gene amplification (measured as EGFR/cell, EGFR
percent gain, EGFR/CEN7, EGFR/CEN7 percent gain),
EGFR- and K-ras-activating mutations, EGFR intron 1 CA
repeat status, and EGFR, pAKT, and PTEN protein expres-
sion. High polysomy 7 (CEN7/cell 4) was significantly
associated with OR (p  0.029). EGFR mutation (p 
0.001), EGFR copy number 6.0/cell (p  0.009), and
EGFR percent gain 75 (p  0.035) were also significantly
associated with response to gefitinib.
The effect of expression of downstream signal trans-
duction factors pAkt and PTEN on response was also as-
sessed. All 11 gefitinib-responsive tumors expressed either
EGFR or pAKT protein, whereas 18/63 (29%) of the nonre-
sponders expressed neither protein (p  0.056). Combining
pAKT expression and EGFR mutation data revealed that
patients with pAKT expression and EGFR mutations had a
significantly higher response rate (6/9; 67%) than “any neg-
ative” patients (5/47; 10%, p  0.001). With regard to PTEN
expression, patients with PTEN expression and EGFR muta-
tions had a significantly higher OR (7/12; 58%) than “any
negative” patients (4/42; 10%, p  0.001). None of the 16
double-negative (EGFR mutation and PTEN) patients
responded to gefitinib, compared with a 30% OR (11/37)
for patients with “any positive” value (p  0.023).
Potential Molecular Predictors of PFS and OS
Kaplan–Meier PFS and OS analyses are summarized in
Table 2. OS was significantly longer for patients with chro-
mosome 7 polysomy (3.6 CEN7/cell; median of 16.2
months, 95% CI 6.7–31.3) than for those without (median 6
months, 95% CI 4.9 to 8.8; p  0.015; Figure 2A). Never-
theless, the association between PFS and chromosome 7
polysomy was found to be not significant. Both OS and PFS
were significantly longer for patients with EGFR mutations
(median 23.8 and 13.6 months, respectively, 95% CI 9.4 to
36.7 and 4.5 to 17.5) than for patients without mutations
(median 7.3 and 3.3 months, 95% CI 5.5–11.4 and 1.9–3.9,
p  0.046 and 0.001, Figure 2B). Patients with IHC expres-
sion of pAKT or PTEN survived somewhat longer than
patients lacking expression of these markers, but these com-
parisons were only marginally significant (p 0.10). Patients
with EGFR gene amplification (EGFR/CEN7 percent gain
34; median 4.5 months, 95% CI 3.2–6.0) had longer PFS
than patients without (median 2.4 months, 95% CI 1.9–3.5,
p  0.012). PFS was significantly longer for patients with
amplification measured as EGFR/CEN7 1.0 (p  0.022).
IHC expression of EGFR (p  0.077) resulted in marginally
statistically significant longer PFS.
Table 3 shows the association between combined mark-
ers and PFS or OS. Patients whose tumors expressed either
EGFR or pAKT protein (any positive) had marginally longer
PFS (p  0.059) and significantly longer OS (p  0.030;
PFS  3.7 months, 95% CI 2.6–5.0; OS  8.4 months, 95%
CI 5.8–12.5) than those expressing neither protein (PFS 
2.4 months, 95% CI 1.8–3.5; OS  4.7 months, 95% CI
3.9–6.6). Patients with tumors that expressed either EGFR or
PTEN protein (any positive) had significantly longer PFS (4.0
months, 95% CI 2.2–4.9) than patients whose tumor ex-
pressed neither protein (2.9 months, 95% CI 1.8–3.7, p 
0.033).
Chromosome 7 polysomy (CEN 7/cell3.6) combined
with either pAKT or PTEN expression by IHC was associated
with significantly longer OS. Patients with polysomy 7
pAKT tumors (24.5 months, 95% CI 12.5 lower bound)
survived significantly longer than “any negative” patients
(5.9 months, 95% CI 4.9 to 8.7; p  0.002; Figure 2C).
Similarly, patients with polysomy 7 PTEN tumors (24.5
months, 95% CI 4.1 lower bound) survived longer than “any
negative” patients (7.1 months, 95% CI 5.5–9.6; p  0.04;
Figure 2D).
Combining pAKT expression and EGFR mutation
data showed that mutation pAKT patients had longer
PFS (p  0.043) and OS, (p  0.040; PFS  16.3 months,
95% CI 9.8–17.5; OS  24.5 months, 95% CI 17.4–39.5)
than patients with “any negative” value (PFS  3.4 months,
95% CI 2.0–4.3; OS 7.6 months, 95% CI 5.5–11.4; Figure
2E). Similar findings were observed when PTEN expres-
sion was combined with EGFR mutation data. Mutation
PTEN patients had significantly longer PFS (p  0.002)
and OS (p  0.023; PFS  16.6 months, 95% CI 9.0–
19.3; OS  29.8 months, 95% CI 11.5–39.5) than “any
negative” patients (PFS  3.3 months, 95% CI 1.9–4.7;
OS  8.3 months, 95% CI 5.5–12.5; Figure 2F). Muta-
tion PTEN patients also had significantly shorter PFS
(3.8 months, 95% CI 2.0–4.9) than “any positive” patients
(4.3 months, 95% CI 2.6–9.8, p  0.049).
Associations between Molecular Variables
Chromosome 7 polysomy was observed more fre-
quently in tumors with EGFR/CEN7 percent gain 34 (p 
0.008), UC FISH status (p  0.001), and expression of
EGFR (p  0.059). EGFR mutations were detected more
frequently in tumors with EGFR percent gain 75 (p 
0.001), EGFR/CEN7 percent gain 34 (p  0.007), EGFR
copy number 6.0 (p  0.005), and EGFR/CEN7 1.0
(p  0.006). Expression of EGFR protein was significantly
associated with UC FISH status (p  0.014), EGFR
percent gain 75 (p  0.0486), EGFR/CEN7 percent gain
34 (p  0.007), EGFR copy number 6.0 (p  0.002),
and EGFR FISH/CEN7 1.5 (p  0.034).
Expression of pAKT protein was significantly associ-
ated with EGFR gene copy number 6.0 (p  0.038),
polysomy 7 (p  0.018), and UC FISH status (p  0.036).
All six tumors with low trisomy FISH as defined by Cap-
puzzo et al.9 had positive PTEN expression compared with
54% (36/67) with expression in the absence of low trisomy
(p  0.035).
Multivariate Analysis
A stepwise selection method within the logistic regres-
sion model was used to select potential predictors of OR to
gefitinib. This analysis yielded EGFR mutation (p  0.002,
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odds ratio 16.995, 95% CI 2.794–103.386) and tobacco use
(p  0.052, odds ratio 0.162, 95% CI 0.024–0.986) as two
important indicators.
A stepwise selection approach was used within the
Cox proportional hazards model to select potential covari-
ates of OS. The initial model included molecular- and
patient-level covariates. The stepwise selection method
yielded chromosome 7 polysomy (CEN7/cell 3.6) [p 
0.004, hazard ratio (HR) 0.397, 95% CI 0.212–0.744]) and
PTEN expression (p  0.017, HR 0.543, 95% CI 0.329–
0.898) as the two important covariates for OS. We note
here that because the cutpoints of the chromosome 7
polysomy were selected on the basis of an exploratory
analysis, its selection in combination with predefined cri-
teria should be interpreted with caution. A similar stepwise
Cox proportional hazards approach applied to PFS selected
EGFR mutations (p  0.002, HR 0.389, 95% CI 0.212–
0.712) as an important covariate.
DISCUSSION
The EGFR TKI, gefitinib, demonstrated objective re-
missions of 18.4% and 11.8% in phase II trials,13,14 and
TABLE 2. Potential Molecular Prognostic Indicators of Disease Progression and Survival
Variable n
Progression-free
Survival (mo) Log-rank p
Median
Survival (mo) Log-rank p
EGFR mutation 0.001 0.046
No mutation 41 3.3 7.3
Mutation 17 13.6 23.8
EGFR expression 0.076 0.748
Not detected 35 2.5 8.5
Present 47 4.2 6.9
UC FISH status 0.961 0.545
Negative 45 2.6 7.3
Positive 36 3.9 7.5
EGFR/CEN7 % gain 0.012 0.078
34 41 2.4 6.0
34 40 4.5 10.3
CEN7 polysomy 0.346 0.015
3.6/cell 63 2.9 6.0
3.6/cell 18 4.2 16.2
EGFR/CEN7 0.022 0.153
1 22 2.0 6.0
1 59 4.1 7.6
Median intron 1 CA* 0.544 0.435
16 25 4.3 9.0
16 33 3.9 8.0
CA repeat SOA* 0.150 0.109
34 30 3.3 6.3
34 28 4.8 12.7
pAkt expression 0.758 0.094
0 39 3.2 5.8
1 to 4 35 3.3 9.6
PTEN expression 0.127 0.091
0 31 3.3 5.9
1 to 4 43 3.4 9.0
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; UC FISH, see Materials and Methods
section; CEN7, centromere 7.
*Median EGFR intron 1 CA repeat allele and sum of alleles (SOA).
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another TKI, erlotinib (Tarceva, OSI Pharmaceuticals),15 pro-
duced a response rate of 12.3% in previously treated pa-
tients.16 In subsequent phase III trials in which EGFR TKIs
were compared with placebos, gefitinib demonstrated a non-
significant trend for longer survival,7 whereas erlotinib was
associated with a moderate but significant prolongation of
survival.2
Recent reports describe the possible prognostic and
predictive value of EGFR-activating mutations (exons 18, 19,
and 21), high EGFR copy number, and perturbations of
downstream proteins in the EGFR pathway in NSCLC pa-
tients treated with EGFR TKIs.9,17–25 In the present study, all
of these molecular markers were analyzed in a new patient set
along with polysomy for chromosome 7, the location of the
EGFR gene. Chromosome 7 polysomy can be defined in a
number of ways, including average chromosome 7 copies per
cell and percentages of cells with various chromosome 7 copy
numbers. Different definitions of chromosome 7 polysomy
were examined in the present study to determine which
definition provided the best prognostic value. Similar defini-
tions of EGFR gene status, in addition to gene amplification,
were also evaluated.
Similar to results observed in trials conducted in Asian
countries20–22 and Spain,23,24 significantly higher response
(p  0.001), longer PFS (p  0.001), and longer OS (p 
0.046) were observed in our patients whose tumors harbored
EGFR-activating mutations. Two groups have reported that
EGFR mutations did not predict survival. In one study, EGFR
mutations were associated with significantly higher response
and longer PFS, but survival analysis showed a nonsignificant
FIGURE 2. Kaplan–Meier curves
comparing survival in patients with
and without tumors exhibiting (A)
chromosome 7 polysomy, (B) EGFR-
activating mutations, (C) chromo-
some 7 polysomy with pAkt stain-
ing, (D) chromosome 7 polysomy
with PTEN staining, (E) EGFR-acti-
vating mutations with pAkt stain-
ing, and (F) EGFR-activating muta-
tions with PTEN staining.
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trend for longer OS.9 EGFR mutations were associated with
neither response nor OS in the other study, but more than half
of the EGFR mutations were outside exons 18, 19, and 21.25
Although controversy persists, our observations add to the
growing evidence that EGFR mutations are important predic-
tors, not only for response to TKIs but also for survival.
High EGFR gene copy number also has been identified
as a positive indicator for TKI efficacy. Cappuzzo et al.9
defined tumors as FISH if they had at least four copies of
EGFR in at least 40% of the cells, if EGFR/chromosome 7
was at least 2, or if at least 15 copies of EGFR per cell were
present in at least 10 % of the cells (UC FISH). FISH
tumors were associated with significantly better response,
PFS, and OS. Similar FISH criteria were applied to patients
in a phase III Canadian trial25 in which FISH tumors had
significantly longer survival over placebo in univariate anal-
yses, but not in multivariate analyses. Our analyses did not
detect a significant survival benefit in patients with UC
FISH status. These discrepancies may be attributable to the
smaller sample size in the current study or to differences in
specimen evaluation (e.g., see clusters evaluation in the
Methods section).
TABLE 3. Epidermal Growth Factor Receptor (EGFR) Expression, Activating Mutations, and
Chromosome 7 Polysomy, Combined with pAkt or PTEN Expression as Potential Prognostic
Indicators of Survival
Variable n
Progression-free
Survival (mo) Log-rank p
Median
Survival (mo) Log-rank p
EGFR expression, pAkt expression 0.059 0.030
EGFR, pAKT 18 2.4 4.7
Any positive 56 3.7 8.4
EGFR expression, PTEN expression 0.033 0.304
EGFR, PTEN 15 2.9 5.8
Any positive 59 4.0 8.0
UC FISH status,* pAkt expression 0.555 0.058
EGFR, pAkt 20 4.9 12.0
Any negative 53 3.0 6.0
EGFR % gain, pAkt expression 0.173 0.057
EGFR 75, pAkt 14 9.0 15.0
Any negative 59 2.9 6.0
EGFR mutation, pAkt expression 0.043 0.040
EGFR mut, pAkt 9 16.3 24.5
Any negative 48 3.4 7.6
EGFR mutation, PTEN expression
EGFR mut, PTEN 12 16.6 0.002 29.8 0.023
Any negative 42 3.3 8.3
EGFR mut, PTEN 16 3.8 0.049 8.0 0.360
Any positive 38 4.3 10.6
EGFR/CEN7 % gain, PTEN expression 0.003 0.004
EGFR 34, PTEN 21 7.5 19.5
Any negative 52 2.6 5.9
CEN 7 polysomy, pAkt expression 0.332 0.002
CEN 7 3.6/cell, pAkt 11 5.5 24.5
Any negative 62 3.0 5.9
CEN 7 polysomy, PTEN IHC 0.404 0.040
CEN 7 3.6/cell, PTEN 9 4.1 24.5
Any negative 64 3.2 7.1
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; CEN7, centromere 7.
*EGFR high polysomy or gene amplification as defined by Cappuzzo et al.9 UC FISH status.
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EGFR gene copy number has been correlated with
protein expression in NSCLC.26 EGFR protein expression has
been evaluated directly by several investigators using differ-
ent anti-EGFR antibodies and various definitions of “posi-
tive.” Defining positive EGFR expression as tumors contain-
ing 1% of cells with EGFR-positive staining or according
to criteria described by Cappuzzo et al.9 or Tsao et al.,25 our
analyses failed to show that EGFR protein expression was
significantly related to response, PFS, or OS.
Cappuzzo et al.9 report that expression of pAKT by
IHC in conjunction with EGFR FISH positivity, EGFR mu-
tation, or EGFR protein expression was associated with
significantly higher OR, longer PFS, and longer OS. Simi-
larly, we observed significantly longer survival in patients
with pAKT tumors (staining in1% of cells) and any of the
following: EGFR by IHC, UC FISH status, or the presence
of EGFR mutation. Nevertheless, in multivariate analyses,
PTEN expression in combination with high chromosome 7
polysomy, and not pAKT, was most prognostic for survival.
The association with OS, but not PFS, may reflect com-
plications of secondary treatments or a more indolent
course of disease in some patient subgroups. Our results
are consistent with those of other investigators27 who did
not find a positive association between response and PTEN
expression alone.
In the current study, multivariate analyses revealed that
increased chromosome 7 copy number (3.6/cell) was the
strongest prognostic indicator of OS (p  0.004). The po-
tential predictive value of chromosome 7 polysomy has not
been previously described. The relative simplicity of deter-
mining chromosome 7 polysomy, compared with EGFR mu-
tation analysis or demonstrating that a tumor is FISH-posi-
tive,9 suggests that additional study of this marker is
warranted. A clinically applicable test for selecting NSCLC
patients for TKI therapy must be sufficiently simple and
reproducible for use in clinical laboratories.
Polysomy 7 is a frequent event in NSCLC, and genes
found in amplified regions of chromosome 7 include several
potential effectors of tumorigenesis.28–30 Moreover, gain of
chromosome 7 in selected cytogenetic backgrounds may
define cell populations with particular phenotypic proper-
ties.12,31 On the basis of the association with OS in the present
study, chromosome 7 polysomy may be a direct or indirect
marker for distinct biology that renders tumors sensitive to
EGFR inhibition.
In summary, chromosome 7 polysomy (3.6/cell) was
associated with significantly improved survival after gefitinib
treatment in NSCLC patients. Regarding previously studied
biomarkers, the current results are consistent with reports that
EGFR mutations have prognostic value in NSCLC patients
treated with EGFR TKIs. Although our study did not show a
significant association between FISH positivity as defined by
Cappuzzo et al.9 and survival in this small patient group, there
was a significant association between FISH positivity and
other prognostic biomarkers. Furthermore, the effects of
PTEN and pAKT expression suggest that the state of these
markers may influence the prognostic value of polysomy 7 or
other EGFR determinants. These observations also raise pos-
sibilities of combining other agents with EGFR TKIs. Further
studies with placebo arms are required to determine the true
predictive value of this biomarker.
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